NeoStem Inc. is an international biopharmaceutical company. The company operates in three segments: Cell therapy (United States), regenerative medicine (China) and pharmaceutical manufacturing (China). NeoStem is a provider of adult stem cell collection, processing and storage services in the United States, enabling healthy individuals to donate and store their stem cells for personal, therapeutic use. In addition, the company collects and stores cord blood cells of newborns, which helps to ensure a supply of autologous stem cells for the child should they be needed for future medical treatment. In January 2011, NeoStem completed the merger with Progenitor Cell Therapy LLC. In October 2011, the company acquired Amorcyte Inc.
The information provided below is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.
Due to permission requirements, not all quotes are shown.
NeoStem Inc. Content
an Article from BioTeusdays.com about NBS's AMR-001 Heart Trials
"NeoStem Unfazed by Hiccup over Its AMR-001 Cardiovascular Stem Cell Treatment" in Forbes (9/27/13)
Back to Top